SPDL1

Across TCGA pan-cancer cohorts, SPDL1 RNA is linked to patient survival in 31 of 34 cancer types, making it the most broadly survival-associated SPDL1 data layer compared with 9 for mutation status and 4 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher SPDL1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated SPDL1 expression acts as an unfavorable survival marker, although some lineages such as THYM and GBM show a favorable association.

MESO, ACC, and LIHC are the cancer types where SPDL1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.401	0.679	<.001	111	view →
ACC	DFS	Median	All	0.429	0.730	<.001	101	view →
LIHC	DFS	Median	All	0.438	0.643	<.001	97	view →
KIRP	DFS	Median	All	0.776	0.927	<.001	92	view →
HNSC	OS	Median	All	0.470	0.715	<.001	76	view →
UCEC	DFS	Tertile	All	0.637	0.869	<.001	70	view →
LUAD	OS	Tertile	All	0.738	0.870	<.001	54	view →
PAAD	DFS	Tertile	All	0.147	0.423	<.001	48	view →
ESCA	DFS	Tertile	All	0.380	0.629	<.001	41	view →
SARC	DFS	Median	All	0.405	0.620	<.001	37	view →
KICH	DFS	Quartile	II,III,IV	0.321	0.851	.008	33	view →
LGG	OS	Tertile	All	0.719	0.865	<.001	33	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 31 lineages.

SPDL1–MESO (OS)

Open the MESO breakdown →